SCPS (Scopus BioPharma) 3-Year RORE % : 0.00% (As of Jun. 2023)


What is Scopus BioPharma 3-Year RORE %?

Scopus BioPharma SCPS 3-Year RORE % is 0.00 as of Jun. 2023.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Scopus BioPharma's 3-Year RORE % for the quarter that ended in Jun. 2023 was 0.00%.

The industry rank for Scopus BioPharma's 3-Year RORE % or its related term are showing as below:

SCPS's 3-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -11.53
* Ranked among companies with meaningful 3-Year RORE % only.

Scopus BioPharma  (OTCPK:SCPS) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.

Scopus BioPharma 3-Year RORE % Related Terms

Scopus BioPharma 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Scopus BioPharma's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scopus BioPharma 3-Year RORE % Chart

Scopus BioPharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
3-Year RORE %
Get a 7-Day Free Trial 0.00 0.00 76.73 56.70 -6.15

Scopus BioPharma Quarterly Data
Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.36 2.83 -6.15 -16.98 -41.61

SCPS vs AMPE, DRMA, SPRC: 3-Year RORE % Comparison

For the Biotechnology subindustry, Scopus BioPharma's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scopus BioPharma 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scopus BioPharma's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Scopus BioPharma's 3-Year RORE % falls into.


Scopus BioPharma 3-Year RORE % Calculation

Scopus BioPharma's 3-Year RORE % for the quarter that ended in Jun. 2023 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.32--1.339 )/( -2.449-0 )
=1.019/-2.449
=-41.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2023 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 0.00 mean?
Scopus BioPharma (SCPS) has a 3-Year RORE % of 0.00 as of Jun. 2023. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Scopus BioPharma and its competitors.
Is Scopus BioPharma's 3-Year RORE % too high?
Scopus BioPharma's current 3-Year RORE % is 0.00.
How does Scopus BioPharma's 3-Year RORE % compare to AMPE and DRMA?
Scopus BioPharma's 3-Year RORE % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Scopus BioPharma and its competitors. Scopus BioPharma's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scopus BioPharma stock overvalued right now?
Scopus BioPharma (SCPS) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Scopus BioPharma (SCPS), the current 3-Year RORE % is 0.00 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scopus BioPharma Business Description

Address 420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.